https://www.live-feeds.com/feed/new-tumor-cases-show-common-gene-therapy-tool-can-come-with-riskContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/new-tumor-cases-show-common-gene-therapy-tool-can-come-with-riskhttps://www.live-feeds.com/feed/new-tumor-cases-show-common-gene-therapy-tool-can-come-with-risk#u193918Wed, 11 Nov 2026 11:51:38 +0000Novartis has confirmed nine reported cases of tumors in children treated with its spinal muscular atrophy gene therapy, Zolgensma, prompting an investigation by the Food and Drug Administration. Seven of the tumor cases are newly disclosed. The rare genetic disease treatment uses a viral vector that has raised safety concerns regarding DNA integration. Advocates are sounding alarms on social media and SMA patient groups are actively seeking more details from doctors about potential treatment risks.Why it mattersThe spinal muscular atrophy therapy Zolgensma relies on an adeno-associated viral v